SITEMAP

• Products
  • Adacel®
  • Aubagio®
    • Aubagio vs Ofatumumab
  • Beyfortus®
    • International Recommendation
      • Nirsevimab International Recommendation
    • Conferences
      • Implementing Beyfortus successfully
      • Beyfortus®, an innovative immunization
      • Beyfortus in Action ECMMID
      • 2024 RSV International Congress - ESPID
      • 2024 RSV International Congress ECMMID
    • Real World Evidence
      • Implementing Beyfortus successfully (ES)
      • Implementing Beyfortus successfully (FR)
      • Implementing Beyfortus successfully (US)
      • Beyfortus in Action
      • Real World Evidence Impact of universal immunization with Nirsevimab
    • Clinical Experience
      • Nirsevimab : Clinical Experience
  • Cablivi®
    • HERCULES Study
      • Study Design
      • Hercules Summary
      • Platelet Count Normalization
      • aTTP-Related Events
      • Recurrences
      • Healthcare Resource Utilization
      • CABLIVI Safety Profile
    • aTTP Diagnosis and Treatment
      • Mechanism of Disease
      • CABLIVI Mechanism of Action
      • ISTH TTP Guidelines
    • Early Treatment Initiation
      • Real-World Evidence Studies
        • CNR-MAT Registry Study
        • Spanish
        • REACT-2020 and Aggregated Analysis
        • Italian
      • ISTH TTP Guidelines
      • CABLIVI-Specific Treatment Recommendation
      • Post-HERCULES
    • Delay in CABLIVI Start
      • Patient Outcomes
      • Active Disease
    • aTTP Sphere Digital Case Library
      • aTTP Sphere Digital Case Library - Kuwait
      • aTTP Sphere Digital Case Library - Qatar
      • TTP Patient Case Study in UAE
      • TTP Patient Case Study in KSA
      • TTP Patient Case Study in UAE
    • Cablivi® aTTP Patients Voice
  • Cerezyme®
  • Clexane®
    • Surgical Patients
    • Hemodialysis
  • Dupixent®
    • Atopic Dermatitis
    • Dupixent® COPD
    • Dupixent Asthma
    • Nasal Polyps
    • The Burden of AD through Dr. Ayman Alnaeem’s Expertise/eyes
    • Dr. Ayman Alnaeem’s Very First Dupixent Patient Experience
    • How Dupixent Changed Dr. Ayman AlNaeem’s Approach in AD Treatment
    • A Message to You from Dr. Ayman AlNaeem
    • The Burden of AD by Dr. Paula Nelson
    • Dr. Paula Nelson’s Very First Dupixent Patient Experience​
    • Dr. Paula’s insights on treating AD patients with Dupixent
  • Fabrazyme®
    • Quantifying the Effect of Fabrazyme
    • Canadian Fabry Disease Initiative
    • Long Term Renal Function
  • Lemtrada®
  • Myozyme®
  • Praluent®
    • Praluent®
      • LDL-C Control
      • Tolerability
      • Patients at CV Risk
      • Starting Praluent®
    • It's Praluent of Course
      • Of Course
      • What is PRALUENT®?
      • Why choose PRALUENT®?
      • How to use PRALUENT®?
  • Sarclisa®
    • Sarclisa®
    • Sarclisa KD®
    • Sarclisa PD®
  • Soliqua®
    • For a Peaceful Ramadan
    • Soli-Simplify Study
    • Soliqua SoliD®
    • Soliqua Easy Start®
    • Soliqua Guidelines®
    • Soliqua Data Set®
    • Soliqua Simplicity®
    • Soliqua Safety®
    • Soliqua®
  • Toujeo®
    • Toujeo for a Peaceful Ramadan
    • Wall of Evidence
    • Toujeo T1DM
      • OneCare
      • Edition Junior
      • UltraFlexi-1
      • Type-1 Meta Analysis
      • Guidelines
    • Toujeo T2DM
      • Deliver-G
      • Guidelines
    • How to Start
    • Toujeo Innovation
      • Toujeo Upgrade to Win
  • Xatral®
• Events
  • Cardiovascular
  • Diabetes
    • 2024
      • Dia-Tour: Navigating New Destinations in Diabetes Management
  • Neurological Disorders
    • 2022
      • What is Epilepsy
    • 2023
      • World Epilepsy Day Podcast Ep. 3
      • World Epilepsy Day Podcast Ep. 2
      • World Epilepsy Day Podcast Ep. 1
      • Sir Robin Murray updates us on Schizophrenia and it’s treatments
    • 2026
      • MS pulse - Tracking the hidden drivers of MS progression
  • Atopic Dermatitis
    • Type II Summit 2025
• Legal Notice
• Cookie Policy
• Privacy Policy
• Login
• Patient Support
  • Patient Support Articles
  • Atopic Dermatitis
  • Cardiovascular
    • 2022
      • Act now for ACS patients by Prof. Mohamed Balgeith
    • Act Now for your ACS Patients
    • Are You Ready for 146? Achieving Optimal LDL-C Levels
    • Are You Ready for 556? Achieving Critical LDL-C Targets
    • Exploring the 556/146 Concept: Insights from Leading Experts
    • Understanding the 556/146 Concept: Insights from Leading Experts
    • 556/146 for Lipid Management after ACS
  • Diabetes
    • Tools and Resources
  • Rare Diseases
• Search
• Activate your Sanofi Account
• Oman Contact Details
• Events Calendar
  • My Lipid webinar 17 April
  • Dia-Tour Webinar: Smart Choices for Intensification
  • Insulin Initiation & Treatment Simplification for T2D - DiaTour
  • Smart Choices For Intensification & Treatment Simplification Options
• Science
  • Cutting Edge Science
  • Inspiration and Innovation
  • Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
    • Cutting Edge Science
      • 2024
      • 2025
        • TTP Patient Case Study in Kuwait
  • Asthma
    • Cutting Edge Science
      • 2024
        • Severe Asthma Biomarker's
        • The Vital Role of Lung Function in Asthma Care
        • Sever Asthmatic patients with OCS
        • Asthma Clinical Remission: The Benchmarks for Eliminating Airway Inflammation and Symptoms
        • Fractional exhaled nitric oxide (Feno)
        • Airway Hyperresponsiveness
          in Asthma
        • ON-TREATMENT ASTHMA REMISSION: MOVING BEYOND CONTROL
      • 2025
        • FeNO Is a Clinically Useful Biomarker of Type 2 Inflammation in Pediatric Patients With Asthma
        • Mucus Plugging Is a Key Component of Remodeling
          in Asthma, Leading to Fixed Airway Obstruction
        • VESTIGE study
        • VESTIGE Trial Results: Dupilumab in Type 2 Asthma
        • Pediatric Management
        • Assessing Pediatric Lung Function
        • Understanding Airway Obstruction: The Role of Mucus Plugging in Asthmatic Disease
        • The Role of Mucus Plugging in Asthma and Its Clinical Burden
      • 2026
        • IL-4, IL-13, AND IL-5 ARE DRIVERS OF SYSTEMIC TYPE 2 INFLAMMATION
  • Atopic Dermatitis
  • Bullous Pemphigoid
    • 2025
      • What is Bullous Pemphigoid
      • Patient morbidity and mortality in BP
      • Pathophysiology of Bullous Pemphigoid
      • Treatments and challenges for bullous pemphigoid
      • Considerations for bullous pemphigoid management
  • Cardiovascular
    • Atherothrombosis
      • Cutting Edge Science
        • Innovation
          • 2022
          • 2023
        • 2022
        • 2023
    • Dyslipidemia
    • Hypertension
    • Thrombosis
  • Chronic Obstructive Pulmonary Disease
  • Diabetes
    • Cutting Edge Science
      • Innovation
      • 2024
        • New Horizon in management of high-risk patients with Diabetes
        • Effective Treatment Simplification
  • Eosinophilic Esophagitis
  • Immune Thrombocytopenia ITP
    • Cutting Edge Science
      • 2025
        • Interplay between the innate and adaptive immunity
        • Complex immune dysregulation impact on QoL
        • Rilzabrutinib a BTK inhibitor
        • The pathophysiology of ITP stems from complex immune dysregulation drives thrombocytopenia and inflammation
  • Multiple Myeloma
  • Multiple Sclerosis
    • Smoldering Neuroinflammation
  • Nasal Polyps
  • Neurological Disorders
    • Cutting Edge Science
  • Prurigo Nodularis
    • Cutting Edge Science
      • 2024
        • Practical Approach in Understanding PN Pathophysiology
  • Rare Diseases
    • Cutting Edge Science
      • Innovation
      • 2025
        • Every Moment Matters: Navigating Diagnosis of Fabry Disease
        • Safety and efficacy of Avalglucosidase Alfa versus Alglucosidase Alfa in patints with Late-Onset Pompe Disease (COMET): a phase 3, randomized, multicentral study results
        • Long-term Safety and Efficacy of Avalglucosidase Alfa IN Patients with Late-Onset Pompe Disease (NEO-EXT)
    • Gaucher
      • Cutting Edge Science
    • Fabry
      • Cutting Edge Science
    • Pompe
      • Cutting Edge Science
    • ASMD
      • Cutting Edge Science
  • Vaccines
    • Influenza
    • RSV
      • Cutting Edge Science
        • 2023
          • RSV
          • All Infant Protection
          • RSV History
          • Burden of Disease
          • Rattle
        • 2024
          • RSV Burden in Infants
          • Saudi initiatives on Bronchiolitis Recommendations
        • 2025
          • RSV Burden in Jazan
          • Beyond High-Risk: Expanding RSV Protection for Newborns and Infants
          • New horizon of RSV lower respiratory tract disease LRTD in infants: Reflection on two seasons of prevention
          • Nirsevimab RWD Metanalysis
          • Kuwait taking the lead in RSV protection for all infants in the Middle east
          • Ensuring overall RSV prevention in every individual Dr. Alia Podcast
    • Mass Gathering
      • Cutting Edge Science
        • 2025
          • Infectious Disease During Mass Gathering
• Register